Moses Makunje

Director of Finance/CFO at NUVATION BIO INC.

Net worth: 27 803 $ as of 2024-04-29

46 year

Health Technology

Commercial Services

Profile

Moses Makunje is currently the Chief Financial & Accounting Officer at Nuvation Bio, Inc. He previously worked as the Corporate Controller at Maze Therapeutics, Inc. from 2019 to 2020.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
NUVATION BIO, INC. CLASS A 0.00%	2024-02-28	10,612 ( 0.00% )	27 803 $	2024-04-29

Moses Makunje active positions

Companies	Position	Start
NUVATION BIO INC.	Director of Finance/CFO	2023-11-26

All active positions of Moses Makunje

Former positions of Moses Makunje

Companies	Position	End
Maze Therapeutics, Inc. Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.	Comptroller/Controller/Auditor	2020-06-30

See the detail of Moses Makunje's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Moses Makunje's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
NUVATION BIO INC.	Health Technology

Private companies	1
Maze Therapeutics, Inc. Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.	Commercial Services